Philips affiche une croissance des ventes, une rentabilité et des flux de trésorerie solides ; relève les perspectives pour l’ensemble de l’année
- oct. 23, 2023
- 8 minutes de temps de lecture
Chiffres clés du troisième trimestre
- Le chiffre d'affaires du groupe a augmenté de 11 % à périmètre comparable pour atteindre 4,5 milliards d'euros
- Le résultat opérationnel a atteint 224 millions d'euros, contre une perte de 1 529 millions d'euros au troisième trimestre 2022
- L'EBITA ajusté est en hausse à 457 millions d'euros, soit 10,2 % du chiffre d'affaires, contre 209 millions d'euros, ou 4,8 % du chiffre d'affaires, au troisième trimestre 2022
- Les commandes ont diminué de 9 % par rapport au troisième trimestre 2022 ; le carnet de commandes reste solide
- Le flux de trésorerie opérationnel a progressé pour atteindre 489 millions d'euros, contre 180 millions d'euros au troisième trimestre 2022
- Les plans de restructuration et de productivité sont en bonne voie avec des économies totales de 258 millions d'euros au cours du trimestre
- Les perspectives pour l'ensemble de l'année 2023 ont augmenté avec une croissance des ventes de 6 à 7 % à périmètre comparable et une marge EBITA ajusté de 10 à 11 %
Roy Jakobs, PDG de Royal Philips :
« L'amélioration de nos performances opérationnelles est portée par l'accent mis sur l'exécution dans le but d'améliorer la sécurité et la qualité des patients, de renforcer la fiabilité de notre chaîne d'approvisionnement et de mettre en place un modèle opérationnel simplifié.
Le carnet de commandes reste solide et nous prenons les mesures nécessaires pour améliorer les commandes en raccourcissant les délais entre la commande et la livraison et en capitalisant sur l'impact positif de nos innovations, par exemple dans l'analyse prédictive des données et l'intelligence artificielle sur l'ensemble de notre portefeuille, pour contribuer à améliorer la qualité et l’efficacité de la prestation des soins.
La finalisation du rappel de Philips Respironics reste notre priorité absolue. La réparation des appareils de thérapie du sommeil est presque terminée et celle des ventilateurs est en cours.
Compte tenu de l'amélioration de nos performances, nous relevons encore nos perspectives tant pour les ventes que la rentabilité pour l’ensemble de l’année 2023, et ce, même si des incertitudes persistent dans un environnement géopolitique de plus en plus volatil. Nos progrès renforcent notre confiance dans la réalisation du plan triennal visant à créer de la valeur avec un impact durable. »
Group and segment performance
Sales for the Group increased 11% on a comparable basis to EUR 4.5 billion, driven by growth in all segments and geographies. Adjusted EBITA increased to EUR 457 million, or 10.2% of sales, mainly driven by increased sales, pricing and productivity measures. Operating cash flow and free cash flow increased to EUR 489 million and EUR 333 million respectively in the quarter, driven by higher earnings and improved working capital management.
Comparable order intake (the order book covers around 40% of Group sales) was 9% lower than in Q3 2022. This was mainly due to a high comparison base related to the exceptionally high levels in 2021, lower orders in China, and longer order lead times. The necessary actions are being implemented to enhance supply chain reliability, reduce order lead times, and leverage our innovations to improve comparable order intake. The order book remains around 20% higher than in the period before the global supply chain challenges and will continue to support growth.
Diagnosis & Treatment comparable sales increased 14% in the quarter, with double-digit growth in all businesses. The Adjusted EBITA margin increased to 12.7% from 10.4% in Q3 2022, mainly driven by increased sales, pricing and productivity measures. Comparable order intake was double-digit lower than in Q3 2022 due to long order lead times, a high comparison base related to the high order intake in Q3 2022, and lower orders in China.
Connected Care comparable sales increased 10% in the quarter, with double-digit growth in Monitoring and mid-single-digit growth in Enterprise Informatics. The Adjusted EBITA margin improved to 3.7% compared to -7.5% in Q3 2022, mainly driven by increased sales and productivity measures. Connected Care comparable order intake was mid-single-digit lower than in Q3 2022 due to a high comparison base in Hospital Patient Monitoring related to the expansion and renewal of the installed base in the last few years.
Personal Health delivered quarter-on-quarter performance improvement, with comparable sales increasing by 7%, driven by high- single-digit growth in Personal Care and Oral Healthcare. The Adjusted EBITA margin increased to 18.7%, compared to 14.1% in Q3 2022, due to increased sales, pricing and productivity measures.
Productivity
Supported by significant change management efforts, to date Philips has reduced the workforce by around 7,500 roles, out of 10,000 roles in total planned by 2025. Operating model productivity savings amounted to EUR 142 million in the quarter. Procurement savings amounted to EUR 59 million, and other productivity programs delivered savings of EUR 57 million, resulting in total savings of EUR 258 million in the quarter.
Outlook
Based on Philips’ improved performance year-to-date, the strong order book, and the ongoing actions, the company is further raising the outlook for the full year 2023, although recognizing uncertainties remain in an increasingly volatile geopolitical environment. Philips now expects to deliver 6-7% comparable sales growth and an Adjusted EBITA margin of 10-11% for the full year 2023, with free cash flow at the upper end of the target range of EUR 0.7-0.9 billion. This reinforces Philips’ confidence in delivering on its three-year plan to create value with sustainable impact.
Customer, innovation and ESG highlights
- Philips signed a 10-year, EUR 100 million Enterprise Monitoring as a Service agreement with one of the largest health systems in the US, covering 20 hospitals with over 3,000 beds. The agreement provides the health system with constant access to the latest technology, including software and services, while lowering initial investments.
- Philips launched its new Image Guided Therapy Mobile C-arm System 3000. Its workflow-enhancing features and excellent image quality enable surgeons to deliver enhanced care to more patients, helping alleviate the staff shortages faced by many hospitals.
- Philips launched its ambulatory monitoring offering in Japan, combining Philips ePatch Holter monitors with ECG analysis through AI and advanced algorithms. This innovative approach aims to reduce clinician workload and improve the patient experience.
- Leveraging its leadership in driving sustainable healthcare, Philips completed a hospital-wide joint action plan for Tampere Heart Hospital in Finland to decarbonize its clinical operations. Following similar action plans at Vanderbilt University Medical Center and Champalimaud Foundation, Philips co-developed a roadmap to reduce carbon emissions in patient throughput, technology use, and use of consumables.
- Philips successfully launched the Sonicare DiamondClean 7900 Series electric toothbrush in China on major online shopping channels Alibaba and JD.com. Highlighting increasing customer demand, it claimed the number-one position in the high-end toothbrush category on Alibaba’s Tmall.
Philips Respironics field action for specific sleep therapy and ventilator devices
Globally, over 99% of the sleep therapy device registrations that are complete and actionable have been remediated, while the remediation of the ventilator devices remains ongoing.
Based on the test results to date, Philips Respironics and third-party experts concluded that use of the sleep therapy devices is not expected to result in appreciable harm to health in patients. Following ongoing communications with the FDA, Philips Respironics has agreed with the agency to implement additional testing to supplement current test data.
In October 2023, Philips Respironics received preliminary court approval for the settlement agreement to resolve all economic loss claims in the US Multidistrict Litigation (MDL) related to the recall, for which Philips had recorded a provision of EUR 575 million in Q1 2023. The settlement does not include or constitute any admission of liability, wrongdoing, or fault by any of the Philips parties.
The previously disclosed litigation, including the personal injury and medical monitoring claims, and investigation by the US Department of Justice related to the Respironics field action are ongoing, as are the discussions on a proposed consent decree.
Capital allocation
During the quarter, Philips settled a number of forward purchase transactions entered into under its EUR 1.5 billion share buyback program for capital reduction purposes announced on July 26, 2021, thereby acquiring a total of 4.2 million shares for a total amount of approximately EUR 154 million. Following further settlements in Q4 2023, Philips intends to cancel approximately 15.1 million shares acquired and to be acquired under this program, before year-end. See here for more information on the share buyback program.
Philips Q3 2023 results downloads
Conference call and audio webcast
Roy Jakobs, CEO, and Abhijit Bhattacharya, CFO, will host a conference call for investors and analysts at 10:00 am CET today to discuss the results. A live webcast of the conference call will be available on the Philips Investor Relations website and can be accessed here.
More information about Roy Jakobs and Abhijit Bhattacharya
Visit our results hub for more on our financial and sustainability performance over the past quarter.